The burden of neovascular age-related macular degeneration: a patient’s perspective
Authors Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA
Received 23 August 2018
Accepted for publication 12 November 2018
Published 4 December 2018 Volume 2018:12 Pages 2483—2491
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,2
1Sydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia
Purpose: To quantify the burden and quality of life of patients and their caregivers in a cohort of patients with neovascular age-related macular degeneration (nAMD) in an Australian clinical setting.
Methods: A total of 103 patients undergoing anti-vascular endothelial growth factor (VEGF) therapy for nAMD were asked to complete questionnaires relating to the financial and time burdens of nAMD.
Results: All patients completed the questionnaires. Loss in productivity due to attendance of appointments was 4.4±1.7 hours per month, with additional time lost by caregivers. Financial strain was incurred by direct medical costs associated with intravitreal assessment and injections at an average of AU$199.2±$83.1 per month. Indirect costs incurred averaged $64.8±$79.7 per month. Qualitative indirect costs due to loss of productivity for the patient, unpaid caregivers, and loss of productivity due to premature mortality were also a considerable burden. Overall mean Visual Function Questionnaire and EuroQol 5D-3L scores were correlated with visual acuity and demonstrated patients’ subjective decline in quality of vision.
Conclusion: Management of nAMD carries a substantial burden on patients and caregivers. These results provide important information in understanding the effect of anti-VEGF therapy among patients with nAMD. Together with the quality-of-life burden on the patients, the management of nAMD has a significant societal impact.
Keywords: burden, treatment, anti-VEGF, age-related macular degeneration, Australia, patient perspective
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]